A comprehensive search for microRNAs with expression profiles modulated by oncogenic KRAS: Potential involvement of miR-31 in lung carcinogenesis

Okudela,Koji; Suzuki,Takeshisa; Umeda,Shigeaki; Tateishi,Yoko; Mitsui,Hideaki; Miyagi,Yohei; Ohashi,Kenichi

doi:10.3892/or.2014.3339

A comprehensive search for microRNAs with expression profiles modulated by oncogenic KRAS: Potential involvement of miR-31 in lung carcinogenesis

Authors:
- Koji Okudela
- Takeshisa Suzuki
- Shigeaki Umeda
- Yoko Tateishi
- Hideaki Mitsui
- Yohei Miyagi
- Kenichi Ohashi
View Affiliations

Affiliations: Department of Pathology, Yokohama City University, Graduate School of Medicine, Kanazawa-Ku, Yokohama 236-0004, Japan, Clinical Research Institute, Kanagawa Prefectural Cancer Center Hospital, Asahi-ku, Yokohama 241-8515, Japan
Published online on: July 18, 2014 https://doi.org/10.3892/or.2014.3339
Pages: 1374-1384

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small non-protein coding RNAs that regulate messenger RNA levels, namely microRNAs (miRNAs), have been implicated in the pathogenesis of various diseases. The purpose of the present study was to identify essential miRNAs involved in lung carcinogenesis. Previous studies demonstrated that an investigation into the downstream targets of oncogenic KRAS could be used as a strategy to elucidate the molecular mechanisms involved in lung cancer; therefore, we examined the expression profiles of mRNAs modulated by oncogenic KRAS in the present study. We focused on miR-31 from the miRNAs that were differentially expressed, and evaluated its potential role in the development of lung cancer. miR-31 was upregulated not only by oncogenic KRAS, but also by oncogenic EGFR. The expression of miR-31 was markedly attenuated in some lung cancer cell lines by deleting its host gene locus. The restoration of miR-31 in lung cancer cell lines that lost its expression attenuated their growth activities. The knockdown of miR-31 expression in lung cancer cell lines retaining its expression enhanced anchorage-independent growth activity. These results suggest that miR-31 may be a suppressor that regulates an essential oncogenic pathway, the loss of which may promote lung carcinogenesis.

View Figures

View References

1	Hoffman PC, Cohen EE, Masters GA, et al: Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 38:65–71. 2002. View Article : Google Scholar : PubMed/NCBI
2	Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 350:379–392. 2004. View Article : Google Scholar : PubMed/NCBI
3	Okudela K, Woo T and Kitamura H: KRAS gene mutations in lung cancer: particulars established and issues unresolved. Pathol Int. 60:651–660. 2010. View Article : Google Scholar : PubMed/NCBI
4	Woo T, Okudela K, Yazawa T, et al: Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer. 65:355–362. 2009. View Article : Google Scholar : PubMed/NCBI
5	Okudela K, Yazawa T, Ishii J, et al: Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis. Am J Pathol. 175:2646–2656. 2009. View Article : Google Scholar : PubMed/NCBI
6	Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
7	van Eijk R, Licht J, Schrumpf M, et al: Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One. 6:e177912011.
8	Xu J, He J, Yang H, et al: Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer Biomark. 10:63–69. 2012.PubMed/NCBI
9	Cozens AL, Yezzi MJ, Kunzelmann K, et al: CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol. 10:38–47. 1994. View Article : Google Scholar : PubMed/NCBI
10	Yazawa T, Kamma H, Fujiwara M, et al: Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol. 187:191–199. 1999. View Article : Google Scholar
11	Okudela K, Yazawa T, Suzuki T, Sugimura H and Kitamura H: Role of 3′-phosphoinositides in oncogenic KRAS-induced modulation of shape and motility of airway epithelial cells. Pathol Int. 59:28–37. 2009.
12	Okudela K, Suzuki M, Kageyama S, et al: PIK3CA mutation and amplification in human lung cancer. Pathol Int. 57:664–671. 2007. View Article : Google Scholar
13	Okudela K, Yazawa T, Woo T, et al: Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am J Pathol. 175:867–881. 2009. View Article : Google Scholar : PubMed/NCBI
14	Valastyan S, Reinhardt F, Benaich N, et al: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 137:1032–1046. 2009. View Article : Google Scholar : PubMed/NCBI
15	Augoff K, Das M, Bialkowska K, McCue B, Plow EF and Sossey-Alaoui K: miR-31 is a broad regulator of β1-integrin expression and function in cancer cells. Mol Cancer Res. 9:1500–1508. 2011.
16	Zhang Y, Guo J, Li D, et al: Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med Oncol. 27:685–689. 2010. View Article : Google Scholar : PubMed/NCBI
17	Cottonham CL, Kaneko S and Xu L: miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem. 285:35293–35302. 2010. View Article : Google Scholar : PubMed/NCBI
18	Slaby O, Svoboda M, Fabian P, et al: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 72:397–402. 2007. View Article : Google Scholar : PubMed/NCBI
19	Guan P, Yin Z, Li X, Wu W and Zhou B: Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res. 31:542012. View Article : Google Scholar : PubMed/NCBI
20	Jang JS, Jeon HS, Sun Z, et al: Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 18:3658–3667. 2012. View Article : Google Scholar : PubMed/NCBI
21	Gao W, Yu Y, Cao H, et al: Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother. 64:399–408. 2010. View Article : Google Scholar : PubMed/NCBI
22	Võsa U, Vooder T, Kolde R, et al: Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes Chromosomes Cancer. 50:812–822. 2011.PubMed/NCBI
23	Xing L, Todd NW, Yu L, Fang H and Jiang F: Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol. 23:1157–1164. 2010. View Article : Google Scholar : PubMed/NCBI
24	Yu L, Todd NW, Xing L, et al: Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer. 127:2870–2878. 2010. View Article : Google Scholar : PubMed/NCBI
25	Tan X, Qin W, Zhang L, et al: A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res. 17:6802–6811. 2011. View Article : Google Scholar : PubMed/NCBI
26	Meng W, Ye Z, Cui R, et al: MicroRNA-31 predicts the presence of lymph node metastases and survival in lung adenocarcinoma patients. Clin Cancer Res. 19:5423–5433. 2013. View Article : Google Scholar : PubMed/NCBI
27	Duan L, Yang G, Zhang R, Feng L and Xu C: Advancement in the research on vascular endothelial growth inhibitor (VEGI). Target Oncol. 7:87–90. 2012. View Article : Google Scholar : PubMed/NCBI